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Chronic radiation proctitis represents a challenging condition seen with increased frequency due to the common use of
radiation for treatment of pelvic cancer. Hemorrhagic radiation proctitis represents the most feared complication of chronic
radiation proctitis. There is no consensus for the management of this condition despite the great number of clinical approaches
and techniques that have been employed. Rectal resection represents an available option although associated with high
morbidity and risk of permanent colostomy. The effectiveness of nonoperative approaches remains far from desirable, and
hemorrhagic recurrence represents a major drawback that leads to a need for consecutive therapeutic sessions and combination
of techniques. We conducted a critical review of published reports regarding conservative management of hemorrhagic
chronic radiation proctitis. Although prospective randomized trials about hemorrhagic radiation proctitis are still lacking,
there is enough evidence to conclude that topical formalin therapy and an endoscopic approach delivering an argon plasma
coagulation represent available options associated with elevated effectiveness for interruption of rectal bleeding in patients
with chronic radiation proctitis.
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Radiotherapy (RDT) techniques
have become primary treatments for
pelvic organ cancer, subsequent to im-
provements in these techniques over
the past few decades. After pelvic irra-
diation, the rectum is one of the most
commonly injured organs due to its
fixed position1-3. Its anatomic relation-
ships with the uterine cervix and pros-
tate make it impossible not to irradi-
ate the rectum during RDT regardless
of the target organ4. Radiation procti-
tis (RP) is an adverse effect of RDT to
the rectum , and its prevention and
treatment have become topics of de-
bate. The main purpose of this review
is to discuss current therapies for radia-
tion-induced injury to the rectum,
mainly in its hemorrhagic form.
GENERAL  CONSIDERATIONS
Radiation proctitis can be classi-
fied as acute or chronic. Acute radia-
tion proctitis (ARP) can begin during
or shortly after irradiation but usually
resolves in up to 6 months. It is char-
acterized by diarrhea, intermittent
bleeding, nausea, abdominal pain, mu-
cous discharge, and constipation or
even urinary symptoms. Histological
alterations are usually confined to the
mucosa5, and in general, has a short
duration and improves with conserva-
tive measures. However, about 20% of
the patients with RP require interrup-
tion of the treatment for 1 to 2 weeks
in order to improve clinical status. Fol-
lowing this acute episode most of the
patients remain asymptomatic, but up
to 20% of this contingent will develop
chronic radiation proctitis (CRP)6. The
development of CRP may take up to
2 years and has no relationship with
the occurrence of ARP7.
During the course of radiotherapy,
virtually all patients present symptoms
related to ARP. However, such symp-
toms usually subside from 2 to 3
months after the end of RDT8. Never-
theless, 2% to 10% of the patients de-
velop CRP, usually 6 to 24 months af-
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ter RDT, but clinical symptoms may
appear up to 30 years after treat-
ment9,10.
Chronic radiation proctitis has sev-
eral forms of clinical presentation, in-
cluding mucous rectal discharge,
diarrhea, urgency, pain, and bleeding.
Recto-vaginal fistula, enteric fistula,
cutaneous fistula, perforation, and rec-
tal stenosis can rarely occur. Histologi-
cal alterations are mainly of a vascu-
lar nature, such as subintimal fibrosis
and platelet thrombi in the arterioles
of the submucosa with fibrosis of con-
nective tissue5.
The development of RP is directly
related to the dose of radiation, the ir-
radiated volume, type of radiation ex-
posure, dose fraction regimens, and the
interval between sessions. Smith et al.
reported a 20% incidence of RP with
a radiation dose up to 7.500 Cgy and
a 60% incidence of RP with doses
greater than 7.500 Cgy11.
Other factors predispose to RP, in-
cluding previous abdomino-pelvic
surgery, obesity, diabetes mellitus, hy-
pertension, atherosclerosis, and simul-
taneous chemotherapy. In 1997,
Bertuccelli et al. studied the effect of
the combination of chemotherapy
with RDT in the treatment of rectal
cancer and observed an increase in in-
cidence of severe diarrhea in the group
that received RDT plus chemotherapy
when compared to the group that un-
derwent RDT alone (20% versus
10%)12.
Endoscopic findings of RP are also
variable. Since 1923, when the first en-
doscopic findings were reported, there
have been many attempts to establish
a standardized endoscopic approach to
its diagnosis13. Paleness, erythema, vas-
cular abnormalities, and ulcerations are
easily recognized alterations. However,
in order to correlate the clinical picture
to endoscopic findings, Wachter et al.
proposed a score for RP based on ter-
minology of the World Organization of
Digestive Endoscopy (OMED) and its
5 main alterations, namely telangiecta-
sias, congestion, ulcerations, stenosis,
and necrosis14.
The prognosis of RP remains ob-
scure. Gilinsky et al., in 1983, reported
on 88 patients with RP followed for
more than 8 years. Fifty percent pre-
sented slight to moderate symptoms
with distinct endoscopic findings that
resolved spontaneously in 2 years10.
Nevertheless, 17 patients presented re-
fractory symptoms. Cho et al. observed
that 19 out of 101 patients developed
RP after radiation therapy for prostate
cancer15.
Despite the fact that the incidence
of RP tends to increase with time, RP
still lacks research and attention. It
should be noted that no consensus ex-
ists about its clinical and endoscopic
evaluation and its natural history. Its
behavior and prognosis are not com-
pletely known.
Rectal bleeding due to RP usually
represents a chronic condition, and
anemia is a common finding; some-
times bleeding may be severe. Several
treatments for this presentation have
been used, and as a result of its high re-
currence rate, they were rarely utilized
in a cyclic manner, which makes their
evaluation difficult. We opted to review
and analyze the results of conservative
treatments of hemorrhagic CRP.
Steroids
In 1976, Goldstein et al. observed
clinical improvement of a patient with
radiation-induced proctitis who re-
ceived salicylazosulfapyridine in com-
bination with prednisone16. Subse-
quently, other studies were developed
in an attempt to evaluate the use of
steroids as a therapeutic alternative for
RP, alone and also in combination
with other modalities.
In 1984, Ben Bouali et al. demon-
strated clinical and endoscopic im-
provement in 4 out of 33 patients
treated with daily rectal administration
of 5 mg of betamethasone in combi-
nation with diphenoxylate17. In 1977,
Pajares et al. also observed a decrease
of rectal bleeding after administration
of prednisone18. More recently,
Triantafillidis et al. reported 5 patients
treated for RP with enemas containing
5 mg of betamethasone without any
clinical improvement19.
In a prospective randomized study,
Kochhar et al. compared the use of en-
emas containing prednisolone and 3 g
of oral sulfasalazine in 18 patients to
the use of enemas containing sucralfate
in combination with an oral placebo
in 19 patients for 4 weeks20. Clinical
improvement was appraised by a score
based on the number of bowel move-
ments, bleeding, and tenesmus.
Therapy with sucralfate was more effi-
cient, better tolerated, and cheaper.
Another prospective randomized
study in mice analyzed administration
of 90 mg of hydrocortisone and
showed endoscopic improvement and
better tolerance when compared with
betamethasone enemas21.
Steroids have been used for many
years in the treatment of RP despite
the absence of larger and well-de-
signed studies22. Moreover, steroids
were not able to achieve sustained
resolution of symptoms for patients
with CRP.
Aminosalicylates
Derivatives of 5-aminosalicylic
acids (5ASA), also known as amino-
salicylates, have been the object of re-
search in treatment of RP since the
studies of Menie et al. in 1975 showed
efficiency of the 5-aminosalicylic acid
drugs versus placebo in the prevention
of diarrhea in patients undergoing pel-
vic RDT, as well as studies for their
previous use in the management of in-
flammatory proctitis. Aminosalicylates
act in reducing the production of
prostaglandins in the intestinal mu-
cosa20.
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Goldstein et al. demonstrated the
effectiveness of oral sulfasalazine in
combination with steroid enemas in 1
patient16. Bem Bouali et al. demon-
strated that administration of sulfa-
salazine, in oral or enema form, pro-
vided clinical and endoscopic im-
provement in 60% of patients17. In
1989, Ladas et al. demonstrated that
administration of sulfasalazine in com-
bination with sucralfate enemas was
effective in controlling rectal bleeding
and promoted endoscopic improve-
ment in 1 patient with CRP.23
On the other hand, in 1989, Baum
et al. showed that daily administration
of enemas containing 5ASA for a pe-
riod of 2 to 6 months was not able to
induce clinical, endoscopic, or histo-
logical improvement in 4 patients with
CRP24. Another study of 5 patients
performed by Triantafillidis et al. dem-
onstrated no improvement over 5ASA
enemas.19
We believe that multicenter pro-
spective randomized studies of amino-
salicylates are needed to confirm their
role in the management of RP, but
available evidence suggests that they
are not effective.
Sucralfate
Sucralfate is an aluminum salt that
adheres to the mucous membrane, pro-
moting the formation of a protective
barrier that has been used for many
years in the treatment of peptic ulcers.
Its possible effectiveness for inflamma-
tory proctitis and for colonic bleeding
after endoscopic polypectomy is also
under investigation.
The cytoprotective action of su-
cralfate seems to be derived from the
production of prostaglandins and pro-
motion of epithelial cell proliferation.
In animal models of colitis in mice,
rectal administration of sucralfate in-
duced high E2-prostaglandin levels
and increased cellularity of the co-
lonic mucosa25.
The best route for sucralfate ad-
ministration remains controversial. In
1988, Kochhar et al. used enemas con-
taining 2 g of sucralfate in 4 patients
with hemorrhagic RP and demon-
strated reduced bleeding26. A previous
study by Henriksson et al. in 1987
showed the usefulness of oral sucralfate
administered for 2 to 6 weeks after
RDT in the reduction of bowel move-
ments, mucous discharge, and rectal
bleeding after 1 year27. Another study
by Kochhar in 1991 demonstrated the
superiority of topical sucralfate over
steroid enemas administered in combi-
nation with sulfasalazine20.
In 1996, Stockdale and Biswas re-
ported that administration of enemas
containing 2 g of sucralfate in a patient
with hemorrhagic RP resulted in long-
term control of CRP as revealed from 4
years of follow-up28. Again in 1996, Tada
et al. demonstrated endoscopic improve-
ment of CRP in 6 out of 7 patients
treated with 2 g sucralfate enemas.29
In 1997, O’Brien et al. published
the negative effect of a sucralfate sus-
pension for prevention of ARP30. In
this multicenter Australian study, 86
patients were randomized into 2
groups: 1 group received 3 g sucralfate
enemas and the other group received
a placebo. Enemas were administered
once daily for a period of 2 weeks af-
ter RDT. Sucralfate enemas did not re-
duce symptoms associated with ARP
and therefore should not be recom-
mended in clinical practice.
In 1998, Sasai et al. published 3
cases of patients with hemorrhagic RP
who had undergone previous sulfa-
salazine and steroid treatment without
success. They experienced significant
improvement of rectal bleeding after
daily administration of 4 g of su-
cralfate during 1 to 2 months31. The
authors emphasized the advantages of
oral sucralfate, which include good
tolerance and few side effects associ-
ated with control of the symptoms for
a long period.
More recently in 1999, Kochhar et
al. demonstrated that topical sucralfate
produced sustained resolution of
symptoms, in agreement with previous
authors32. Stockdale and Biswas 28
studied 26 patients with hemorrhagic
RP that were treated with 2 g sucralfate
enemas twice daily. The patients were
examined every 4 weeks in the first 16
weeks of treatment and after that at an
interval of 8 to 12 weeks. Twenty pa-
tients had a significant reduction of
bleeding in the first 4 weeks of treat-
ment, as did another 4 patients after 16
weeks. At a mean of 45 weeks, 7 pa-
tients had some kind of symptomatic
recurrence. However, bleeding ceased
soon after the sucralfate treatment was
reintroduced.
Short-Chain Fatty Acids (SCFA)
During the past few years, many
studies have been performed on short-
chain fatty acids (SCFA) so that knowl-
edge regarding these substances has
increased. Short-chain fatty acids are
organic acids containing from 1 to 6
carbons that are a product of bacterial
metabolism of some carbohydrates in
the colon; they are the main source of
energy for colonocytes. Butyrate is the
most important SCFA and is preferen-
tially metabolized by colonic mucosa
when compared to propionate and ac-
etate. The dependence of the colon re-
lated to the oxidation of SCFA in-
creases towards the rectum, and 70%
of the oxygen consumed by the co-
lonic epithelial cells is used in the oxi-
dation of SCFA33.
The effect of SCFA on rectal and
colonic mucosa has been tested in pa-
tients with RP in an attempt to obtain
healing of mucous lesions33,34. In 1999,
Pinto et al. in a double-blind rando-
mized placebo-controlled trial studied
19 patients with CRP35. They demon-
strated a beneficial effect from admin-
istration of 2 daily enemas with 60
mmol SCFA for 5 weeks in compari-
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son with the administration of an isot-
onic solution. There was a significant
decrease of rectal bleeding with SCFA
as well as an endoscopic improvement.
In 1995, Mamel et al. also demon-
strated the efficacy of enemas contain-
ing 60 mL of SCFA twice daily for 4
weeks in the improvement of 6 pa-
tients with CRP36. In 1996, Al
Sababagh et al. using the same solu-
tion described in the previous studies
achieved clinical, endoscopic, and his-
tological improvement in 7 patients
with hemorrhagic RP37.
These results were not reproduced
by Chen et al. in a prospective study,
where they evaluated the evolution of
12 patients with hemorrhagic CRP for
2 weeks and did not find any signifi-
cant difference in clinical, endoscopic,
and histological aspects of patients
treated with SCFA38.
More recently, Talley et al. com-
pared daily administration of 2 enemas
with 60 mL of butyrate in a concen-
tration of 40 mmol to placebo for 2
weeks in a randomized double-blind
study of 15 patients with CRP. They
found no benefit from SCFA39.
In 1998, Cook and Sellin per-
formed a literature review about SCFA
in the management of colitis33. Regard-
ing RP, the authors observed that stud-
ies showed early reduction of bleeding
episodes, but SCFA had no influence
in other symptoms such as chronic
pain and tenesmus.
In spite of the great progress in the
knowledge of the structure, metabo-
lism, and action of SCFA, there is still
need for additional data to confirm its
effectiveness. Because of these con-
flicting data, there are no commercial
preparations available for clinical use.
Formalin
The use of formalin in the manage-
ment of RP emerged from its use in the
treatment of bleeding tumors of the
bladder and radiation cystitis40,41, 2.
In 1986, Rubinstein et al. success-
fully used a rectal wash with formalin
for the first time in the treatment of
RP42. The authors reported a 71-year-
old patient irradiated for bladder can-
cer who developed diffuse hemor-
rhagic RP. The patient underwent gen-
eral anesthesia and the rectum was ir-
rigated with two liters of 3.6% forma-
lin for 15 minutes, followed by irriga-
tion with saline. An insufflated vesical
probe was used in order to protect the
sigmoid colon. The procedure was re-
peated after 2 weeks and after 3
months. Bleeding episodes immedi-
ately ceased and the patient was
asymptomatic after 14 months.
After these results, many authors
initiated treatments of hemorrhagic
CRP with formalin. In 1993, Seow-
Choen et al. used formalin in 8 pa-
tients with hemorrhagic CRP refrac-
tory to steroids and with a constant
need for blood transfusions43. In this
study, a 4% solution-soaked gauze was
applied to the rectum through a recto-
scope. Patients underwent regional
anesthesia and had their perianal skin
protected to avoid direct contact with
the formalin. Contact between the
gauze and rectal mucosa was main-
tained until the bleeding stopped
(from 2 to 3 minutes). Bleeding ceased
in 7 patients after a single session,
while another patient needed an addi-
tional application.
In 1995, the same authors con-
firmed the effectiveness of direct ap-
plication of formalin solution soaked
gauze in 29 patients followed for 12
months44. In this study, rectal bleeding
ceased right after application in 17 pa-
tients. Four patients needed a second
application (72% success rate). The 5
remaining patients obtained only par-
tial improvement.
The instillation technique pro-
posed by Rubinstein et al. was modi-
fied by 2 groups. One of them used rec-
tal instillation with 4% formalin after
placement of a Foley catheter in order
to delineate the superior limit of the
instillation and protect the normal in-
testine in 14 patients resistant to ster-
oid and/or sulfasalazine treatment45.
Treatment was well tolerated, and 11
patients needed 2 applications while
other 3 patients needed 3 sessions. Af-
ter 6 months, 9 patients were asymp-
tomatic (64%), 3 patients had incom-
plete resolution of symptoms, and 2
had no improvement. Saclarides et al.
reported a study in which aliquots of
50 mL of 4% formalin were instilled
into the rectum for 30 seconds each,
with a total of 400 to 500 mL per ses-
sion in 16 patients. They achieved
complete symptom control in 81% of
after 1 or 2 applications46. Four pa-
tients developed fissures in the anal
verge and 1 developed tenesmus.
The technique of soaked gauze
proposed by Seow-Choen was revised
by 5 groups, with a total of 41 patients.
Complete success rate ranged from
80% to 100% after 1 to 4 sessions (Ta-
ble 1)43,47-51.
Recently, in an Australian study, a
Table 1 - Summarized results of patients with hemorrhagic radiation proctitis
treated with formalin instillation.
Author Number of patients Follow-up (months) Response
Seow-Choen et al.43, 1993 8 4 88%
Biswal et al.47, 1995 16 11 81%
Isenberg et al.48, 1994 2 3 100%
Salvati et al.49, 1996 10 Not reported 100%
Roche et al.50, 1996 6 12 100%
Faragher et al.51, 1997 7 10 100%
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combination of formalin and Nd:YAG
(neodymium yttrium-aluminum-garnet)
laser was used in 14 patients52. First, the
patients underwent an endoscopic
Nd:YAG laser procedure and then were
treated with a formalin application as
described by Seow-Choen. A single ses-
sion was enough for 9 patients, 2 ses-
sions were necessary for3 patients, and
3 sessions forthe other 2 patients. After
a 3-year follow-up, 10 (71%) patients
had no rectal bleeding, and another one
had a significant decrease in bleeding
episodes. Two patients required an op-
eration to manage their symptoms.
After these first published series
with formalin as a therapeutic alterna-
tive for hemorrhagic RP, investigators
have been trying to determine the best
concentration and form of its applica-
tion as well as its side effects. In low
concentrations, formalin is not toxic.
However, high concentrations can result
in severe toxic effects. Additionally, the
nutritional state and smoking can alter
blood levels of formalin. The only re-
ported case of intoxication after rectal
irrigation occurred due to accidental
infusion of 100 mL of 10% formalin.
The patient developed chronic colitis
that resolved after 2 months53.
Evidence suggests that formalin is
very effective in the treatment of
hemorrhagic CRP, mainly in cases in
which the 2 distal thirds of the rectum
are affected. Other advantages of for-
malin application are low cost, low in-
cidence of side effects, availability, and
its easy manipulation.
Endoscopic
Endoscopic management of CRP is
based on endoscopic coagulation in-
duced by Nd:YAG laser, electrocoagu-
lation, or argon plasma coagulation
(APC).
The first description of Nd:YAG la-
ser use in CRP was published by
Leuchter in 1982. The author reported
the success of this technique for the
control of rectal hemorrhage after 4
applications in 1 patient in which he
used 30 shots driven to the endoscopi-
cally identified vascular alterations54.
The effectiveness of the Nd:YAG
laser was confirmed by other authors
in series with a total of 98 patients.
One of the most important was pub-
lished by Viggiono et al. in 1993 re-
porting on 47 patients. After an aver-
age of 2 sessions (7950 joules each), a
79% control rate of rectal bleeding
was achieved55.
In 1998, Swaroop et al. described
the technique for therapy with a
Nd:YAG laser56. Initially, the patient
should undergo a complete colo-
noscopy to determine the extent of the
lesion. With an initial energy of 40 W
and a maximum pulse duration of half
a second, the laser is applied without
direct contact to the mucosa, but with
its tip less than 1 cm away from it. All
visible lesions should be coagulated
in the distal direction. A white clot
should be obtained as a final effect,
avoiding cavities in the intestinal mu-
cosa. Complications of Nd:YAG laser
therapy include tenesmus, abdominal
pain, rectal stenosis, prostatitis, and
recto-vaginal fistula55,57.
Laser therapy for hemorrhagic CRP
was supplanted by argon plasma co-
agulation (APC) because it is more
readily available, cheaper, and requires
fewer safety precautions, while still
yielding excellent results. Argon
plasma coagulation is a diathermy
method in which there is no direct
contact between the electrode and the
patient, and high frequency energy is
applied to the tissue through the ion-
ized argon. This technique is very suit-
able for coagulation of large bleeding
surfaces and features the advantage of
limited penetration (2 to 3 milli-
meters), minimizing the risks of perfo-
ration, stenosis, and fistulization. The
char generated with APC promotes an
interruption of the current passing
through the tissue while Nd:laser con-
tinues to penetrate the tissue until it
is switched off.
Since the first use of APC with a
flexible endoscope described by
Grund et al.58 in 1994, it has gained a
wide popularity. Silva et al. in a study
of 28 patients obtained good results59
and emphasized the possibility of ap-
plication of the argon plasma in any
direction, resulting in excellent access
to vascular lesions. Gas flow eliminates
oxygen from the coagulation area,
avoiding carbonization of the tissue
and smoke production. Moreover,
light produced by gas ionization pro-
motes good visual control of the pro-
cedure. Those authors also propose the
use of 50 W of energy and a 1.5 L/min
flow for the procedure. Fantin et al.
demonstrated the effectiveness of APC
in 7 patients after 2 to 4 applications,
using as parameters an energy of 60 W
and a flow of 3 L/min60.
Other authors have also obtained
good results with APC. Taylor et al.
used APC in 14 patients with hemor-
rhagic CRP61. Bleeding episodes
ceased in 10 patients (71%), although
they needed complementary applica-
tions. The summarized series are re-
ported in table 261-63.
Table 2 - Series and summarized results of patients with hemorrhagic radiation
proctitis treated with argon plasma coagulation.
Author Number of Follow-up Complete Partial
patients (months) Response Response
Buchi et al.62, 1987 3 7 66% 100%
Taylor et al.63, 1993 14 35 50% 50%
O’Connor et al.64, 1989 5 5 100% -
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Argon plasma coagulation has
proven beneficial in almost all avail-
able studies. Use of argon plasma tech-
nology for other applications espe-
cially in surgery increases the useful-
ness of the equipment.
Endoscopic treatment through
electrocoagulation is simple, widely
available, and cheap. Bipolar
electrocoagulation may be safer than
monopolar. Electrocoagulation and
heater probes are readily available at
most hospitals without significant
additional cost. Because of its ready
availability, it is one of our first
options for hemorrhagic CRP. Distal
telangiectasias can be treated
conveniently by this method. All
visible lesions should be treated in a
single session. The most important
technical aspect of telangiectasias
ablation is to use the smallest possible
amount of energy for coagulation,
avoiding formation of deep ulcers.
After the initial session of coagulation,
an interval should be intervene before
reexamination, since coagulated areas
need time for healing.
CONCLUSIONS
Many alternative techniques and
research with other possible therapeu-
tic agents for the treatment of
hemorrhagic CRP, the most frequent
chronic complication of radiation in-
jury to the rectum, are currently under
investigation71-73. The effectiveness of
many therapeutic options has still not
been shown with solid scientific evi-
dence from controlled trials, and basic
research may open a new perspective.
Nowadays, the best alternatives for
management of hemorrhagic CRP
seem to be topical formalin and APC.
Despite all therapeutic strategies
available for the management of CRP,
the best one remains its prevention.
Use of more advanced radiation tech-
niques in the past few decades and in-
troduction of less toxic regimens are
good examples that may contribute to
a decrease in incidence of CRP. How-
ever, the prevalence of CRP may in-
crease as result of widespread use of
radiotherapy for cancer treatment.
Hyperbaric Oxygen Therapy
Hyperbaric oxygen (HBO) has been
used in the treatment of the RP after
previous experiences with other radia-
tion-induced lesions (cystitis and der-
matitis) with satisfactory results.
Its mechanism of action is based
on the decrease of tissue hypoxia with
consequent acceleration of healing
process, restoration of local anti-infec-
tious defenses, and directly toxic ef-
fects to bacteria.
Four publications reported excellent
results with the use of HBO in 8 patients
with hemorrhagic RP64-67. However, 2 re-
cent studies demonstrated more modest
results. The first of these obtained a 56%
rate of good results for 18 patients68. The
other was able to achieve 64% good re-
sults in 14 patients69. These studies were
retrospective with controversial results.
There may be recurrences, and it may
take a long period of treatment for symp-
toms to resolve. In addition to the lack
of scientific support, HBO is an expen-
sive technique that is still restricted to
specialized centers.
RESUMO
COTTI G e col. - Tratamento conser-
vador da retite actínica hemor-
rágica: uma revisão. Rev. Hosp.
Clín. Fac. Med. S. Paulo 58(5):
284-292, 2003.
A retite actínica crônica é uma con-
dição cada vez mais freqüentemente
observada como resultado do crescen-
te emprego da radioterapia no trata-
mento do câncer de órgãos pélvicos.
A manifestação hemorrágica da retite
actínica é a complicação mais comum
dessa doença e seu tratamento é desa-
fiador. Diversas técnicas foram empre-
gadas para o tratamento dessa condi-
ção e não há evidência satisfatória
acerca da melhor forma de controlar os
episódios de sangramento de forma
eficaz e duradoura. A necessidade de
se realizar múltiplas sessões de trata-
mento conservador bem como a asso-
ciação de técnicas freqüentemente ob-
servada no manejo desses pacientes di-
ficulta a interpretação dos resultados.
O objetivo dessa revisão foi avaliar a
segurança e a eficácia das alternativas
clínicas mais freqüentemente emprega-
das no controle da retite actínica
hemorrágica. Ainda que a falta de es-
tudos prospectivos e randomizados
comparando duas ou mais alternativas
terapêuticas impeça uma conclusão
mais definitiva, concluímos que exis-
te suficiente evidência acerca de ele-
vada eficácia e segurança associadas
ao emprego da formalina tópica e da
coagulação por plasma de argônio no
controle do sangramento em pacientes
com retite actínica crônica.
DESCRITORES: Retite. Actínica.
Hemorrágica. Tratamento. Conser-
vador.
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